Notice of Intent to Publish a Funding Opportunity Announcement for Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required)
ID: 355534Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355534
Timeline
    Description

    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) initiative, specifically targeting Tobacco Use Treatment for Cancer Survivors. This initiative aims to fund up to three research projects that will explore and refine strategies to enhance the delivery and sustainability of tobacco use treatment services for cancer survivors, utilizing the UG3/UH3 Exploratory/Developmental Cooperative Agreement activity code, with a requirement for clinical trials. The total estimated funding for this opportunity is $2.4 million, with the application expected to open in late Summer 2024 and close in late Fall 2024, while the anticipated award date is set for July 1, 2025. Interested applicants are encouraged to prepare by reviewing the initiative's presentation available online and should stay tuned for further announcements regarding a pre-application webinar.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)- Lung Cancer Screening (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) initiative, specifically targeting Lung Cancer Screening (LCS). This initiative aims to fund up to three research projects that will develop and test strategies to enhance the delivery and sustainability of high-quality, guideline-concordant lung cancer screening among high-risk populations. The total estimated funding for this program is $2,400,000, with awards structured as Cooperative Agreements under the UG3/UH3 activity code, requiring clinical trials. The NOFO is anticipated to be published in late Summer 2024, with applications due in late Fall 2024, and the estimated award date is set for July 1, 2025. Interested applicants are encouraged to prepare by reviewing related materials and attending a pre-application webinar, details of which will be announced following the NOFO publication.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science, inviting R01 research applications that focus on biomedical and behavioral research to inform tobacco product regulation. This initiative aims to generate scientific data that will enhance public health protections related to tobacco use, with a particular emphasis on fostering diverse perspectives through a simplified peer review framework. The total estimated funding for this program is $4 million, with an award ceiling of $500,000 for each of the anticipated five awards, and the NOFO is expected to be published in Winter 2024, with applications due in Summer 2025. Interested applicants should prepare to submit new applications, as only new proposals will be considered, and further details will be available upon the official release of the NOFO.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)," aimed at accelerating the development of evidence-based cancer interventions that address health disparities among diverse populations in the United States. This initiative will support research that tests the impact of cancer-related interventions on outcomes through a pragmatic trial design, structured in two phases: the UG3 phase for preparatory activities and intervention refinement, followed by the UH3 phase for conducting the trial. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with funding amounts capped at $500,000 for the UG3 phase and $750,000 for the UH3 phase. Interested parties should note that applications are due by November 17, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery and Development of Natural Products for Cancer Interception and Prevention" under the cooperative agreement mechanism. This initiative aims to support innovative projects that focus on the discovery and development of novel natural products that are safe, nontoxic, and effective in intercepting or preventing cancer, with a structured approach divided into two phases: the UG3 phase for initial target selection and assay validation, followed by the UH3 phase for large-scale evaluations and pharmacokinetic assessments. The total funding available for this program is $4.5 million over the fiscal years 2024 to 2026, with a deadline for applications set for June 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at researching the intersection of cancer stigma and HIV stigma in individuals diagnosed with both conditions. This initiative seeks to advance understanding of how these stigmas affect cancer outcomes among HIV-positive individuals, promote stigma reduction interventions, and encourage research in areas with high HIV-cancer burdens. The NIH plans to award up to six R01 grants, each with a ceiling of $500,000, as part of a total estimated funding pool of $5 million, with the NOFO expected to be published in late Summer 2024 and applications due in late Fall 2024. Interested applicants are encouraged to prepare by reviewing related presentations and materials available online.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network (NCTN) - Network Group Operations Centers, which will require a U10 clinical trial. This initiative aims to provide scientific leadership for the development and implementation of multi-disciplinary, multi-institutional clinical trials targeting various cancer types and populations, focusing on late-phase treatment trials and advanced imaging studies. The funding, estimated at $99.3 million, is intended to support the conduct of essential clinical research for adults, adolescents, and children with cancer, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, applicants should prepare their submissions in advance of the anticipated award date of March 1, 2026.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for The confluence of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at exploring the intersection of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer. This initiative seeks to support pilot and exploratory research that enhances understanding of how these dual stigmas affect cancer outcomes and promotes research in both domestic and international contexts, particularly in regions with a high burden of HIV and cancer. The NIH anticipates funding up to three R21 grants, with a total estimated funding of $1,000,000, and the NOFO is expected to be published in late Summer 2024, with applications due in late Fall 2024. Interested applicants are encouraged to prepare by reviewing the initiative's presentation and will find further details on the application process following the NOFO publication.